Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Cremer

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Bone Marrow Transplantation|June 18, 1999
Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantationK Kiel, F W Cremer, C Rottenburger, et al.
Human Genetics|September 2, 2004
A large MSH2 Alu insertion mutation causes HNPCC in a German kindredMatthias Kloor, Christian Sutter, Nicolas Wentzensen, et al.
Orphanet Journal of Rare Diseases|October 24, 2020
Revesz syndrome revisitedMichael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, et al.
British Journal of Cancer|September 14, 2006
Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgeryA Zahlten-Hinguranage, H Goldschmidt, F W Cremer, et al.
Drugs Under Experimental and Clinical Research|January 1, 1985
Comparative in vitro studies with 4-quinolone antimicrobialsD Felmingham, M D O'Hare, M J Robbins, et al.
British Journal of Haematology|March 2, 1999
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell contentM T Voso, S Hohaus, M Moos, et al.
Annals of Hematology|March 22, 2002
Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantationC Gemmel, F W Cremer, M Weis, et al.
European Journal of Human Genetics : EJHG|January 19, 2006
Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumorJens Plaschke, Michael Linnebacher, Matthias Kloor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2005
Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myelomaM S Raab, F W Cremer, I N Breitkreutz, et al.
British Journal of Haematology|August 26, 2004
Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myelomaMarleen H C Bakkus, Yasmina Bouko, Diana Samson, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Bone Marrow Transplantation|June 18, 1999
Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantationK Kiel, F W Cremer, C Rottenburger, et al.
Human Genetics|September 2, 2004
A large MSH2 Alu insertion mutation causes HNPCC in a German kindredMatthias Kloor, Christian Sutter, Nicolas Wentzensen, et al.
Orphanet Journal of Rare Diseases|October 24, 2020
Revesz syndrome revisitedMichael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, et al.
British Journal of Cancer|September 14, 2006
Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgeryA Zahlten-Hinguranage, H Goldschmidt, F W Cremer, et al.
Drugs Under Experimental and Clinical Research|January 1, 1985
Comparative in vitro studies with 4-quinolone antimicrobialsD Felmingham, M D O'Hare, M J Robbins, et al.
British Journal of Haematology|March 2, 1999
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell contentM T Voso, S Hohaus, M Moos, et al.
Annals of Hematology|March 22, 2002
Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantationC Gemmel, F W Cremer, M Weis, et al.
European Journal of Human Genetics : EJHG|January 19, 2006
Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumorJens Plaschke, Michael Linnebacher, Matthias Kloor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2005
Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myelomaM S Raab, F W Cremer, I N Breitkreutz, et al.
British Journal of Haematology|August 26, 2004
Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myelomaMarleen H C Bakkus, Yasmina Bouko, Diana Samson, et al.
Pageof 8